CRO (임상시험수탁기관) 서비스 시장조사 보고서

Report Overview

The contract research organization (CRO) services market is projected to reach USD 129.8 billion by 2029 from an estimated USD 82.0 billion in 2024, at a CAGR of 9.6% during the forecast period.

CRO (임상시험수탁기관) 서비스 시장은 2024년 추정 820억 달러에서 2029년까지 1,298억 달러에 이를 것으로 예측되며, 예측 기간 중 CAGR은 9.6%입니다.

The key factors driving the growth of the CRO services market include increasing initiatives for novel drug development. Moreover, growing demand for precision personalized medicines is an opportunity area for this market.

The CRO services market has been segmented based on type, therapeutic area, end user and region.
 “By type, early development services segment accounted for the second largest share in the CRO services market”
Based on type, the CRO services market is categorized into Clinical Research Services, Early Phase Development Services, Laboratory Services, Consulting Services and Data Management Services. In 2023, the early development services accounted for the second-largest share of the market owing to major factors such as the growing incurred costs and associated stringent regulatory requirements of processes in the different stages (discovery, preclinical) of early phase development.

“By end user, the pharmaceutical and biopharmaceutical companies accounted for the largest share in the CRO services market”
Based on end user, the CRO Services market is segmented into Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies and Academic Institutes. In 2023, the Pharmaceutical & Biopharmaceutical Companies segment accounted for a largest share of the CRO services market. Large share of this market segment can be attributed large number of drug pipeline products of pharma and biotech companies and presence of large number of pharma and biotech companies venturing in the drug development arena.

“North America: the largest share of the CRO Services market”
North America accounted for the largest share of the CRO Services market in 2023. The large share of the North America region can be attributed to a major factor which is the presence of key pharma and biotech players involved in drug research and development. This has consequently led to an increase in the outsourcing of clinical research activities in the region. Besides, the region has a well established healthcare system which further supports the growth of this market through funding and investments.

“Asia Pacific: The fastest-growing region in the CRO Services market.”
The Asia Pacific CRO Services market is projected to grow at the highest CAGR during the forecast period. This is attributed to one of the major factors that is the large patient population that is available along with desired diversity for conduction of clinical trials. Additionally, the overall costs of operations are relatively low in the region which attracts organizations for conduction of trials in the region.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers – 45%, Directors- 30%, and Executives – 25%
• By Country: North America- 35%, Europe- 30%, Asia Pacific- 25%, Latin America- 5%, and Middle East and Africa- 5%

Prominent  Players
• IQVIA Inc. (US)
• Laboratory Corporation of America Holdings (LabCorp) (US)
• Thermo Fisher Scientific Inc. (US)
• Syneos Health (US)
• WuXi AppTec (China)
• Charles River Laboratories (US)
• Parexel International Corporation (US)
• Pharmaron (China)
• ICON Plc (Ireland)
• Medpace (US)
• SGS SA (Switzerland)
• Frontage Labs (US)
• Eurofins Scientific (Luxembourg)
• PSI CRO AG (Switzerland)
• BioAgile (India)
• Firma Clinical Research (US)
• Acculab Life Sciences (US)
• Novotech (Australia)
• KCR S.A. (US)
• Linical (Japan)
• Advanced Clinical (US)
• Allucent (US)
• Clinical Trial Service (Netherlands)
• Guires Inc. (Pepgra Healthcare Pvt. Ltd.) (UK)
• Worldwide Clinical Trials (US)
• CTI Clinical Trial And Consulting (US)

Research Coverage:
This report provides a detailed picture of the CRO Services market. It aims at estimating the size and future growth potential of the market across different segments, such as the type, therapeutic area, end user and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies. 

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the CRO Services market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, opportunities, challenges and trends. 

The report provide insights on the following pointers
• Analysis of key drivers (growth in number of products in pipeline), opportunities (personalized medicine focus), challenges (patient recruitment) and trends (real world data and real world evidence) influencing the growth of the CRO Services market.
• Market Development:  Comprehensive information about lucrative markets- the report analyses the CRO Services market across varied regions.  
• Market Diversification: Exhaustive information about new service, untapped geographies, recent developments, and investments in the CRO Services market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like IQVIA Inc. (US), Laboratory Corporation of America Holdings (US), Thermo Fisher Scientific Inc. (US), ICON Plc (Ireland), WuXi AppTec (China), Syneos Health (US), Charles River Laboratories (US), Fortrea, Inc. (US), Pharmaron (China), Eurofins Scientific (Luxembourg) and Medpace (US) among others in the CRO Services market. 

Table of Contents

1            INTRODUCTION            66

1.1         STUDY OBJECTIVES      66

1.2         MARKET DEFINITION   66

1.3         INCLUSIONS & EXCLUSIONS     66

1.4         MARKET SCOPE             67

1.4.1      MARKETS CONSIDERED             67

1.4.2      REGIONS CONSIDERED 68

1.4.3      YEARS CONSIDERED     68

1.4.4      CURRENCY CONSIDERED          68

1.5         RESEARCH LIMITATIONS           69

1.6         STAKEHOLDERS            69

1.7         SUMMARY OF CHANGES            69

1.7.1      RECESSION IMPACT: CRO SERVICES MARKET   70

2            RESEARCH METHODOLOGY     71

2.1         RESEARCH DATA           71

FIGURE 1           RESEARCH DESIGN       71

2.1.1      SECONDARY DATA       72

FIGURE 2           SECONDARY DATA SOURCES    72

2.1.2      PRIMARY DATA 73

FIGURE 3           BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 73

2.2         MARKET SIZE ESTIMATION       74

FIGURE 4           MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023              74

FIGURE 5           MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023             75

FIGURE 6           ILLUSTRATIVE EXAMPLE OF IQVIA INC.: REVENUE SHARE ANALYSIS, 2023 76

FIGURE 7           MARKET VALIDATION FROM PRIMARY EXPERTS           77

2.2.1      MARKET SIZE ASSESSMENT AT SEGMENTAL LEVEL       77

FIGURE 8           MARKET SIZE ESTIMATION: TOP-DOWN APPROACH    77

2.3         MARKET GROWTH FORECAST  78

FIGURE 9           CAGR PROJECTIONS, 2024–2029 79

FIGURE 10         GROWTH ANALYSIS OF DRIVERS, OPPORTUNITIES, AND CHALLENGES IN CRO SERVICES MARKET           79

2.4         MARKET BREAKDOWN & DATA TRIANGULATION          80

FIGURE 11         DATA TRIANGULATION METHODOLOGY         80

2.5         STUDY ASSUMPTIONS  80

2.6         RISK ANALYSIS 81

2.7         IMPACT OF ECONOMIC RECESSION ON CRO SERVICES MARKET              81

TABLE 1             GLOBAL INFLATION RATE PROJECTION, 2021–2028 (% GROWTH)         81

TABLE 2             US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)  82

TABLE 3             US HEALTH EXPENDITURE, 2023–2030 (USD MILLION)  82

3            EXECUTIVE SUMMARY 83

FIGURE 12         CRO SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)              83

FIGURE 13         CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION) 84

FIGURE 14         CRO SERVICES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)          85

FIGURE 15         GEOGRAPHICAL SNAPSHOT OF CRO SERVICES MARKET              86

4            PREMIUM INSIGHTS      87

4.1         CRO SERVICES MARKET OVERVIEW      87

FIGURE 16         INCREASING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET 87

4.2         NORTH AMERICA: CRO SERVICES MARKET,  BY COUNTRY AND TYPE, 2023      88

FIGURE 17         US AND CLINICAL RESEARCH SERVICES TO DOMINATE NORTH AMERICAN CRO SERVICES MARKET IN 2023       88

4.3         CRO SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)              89

FIGURE 18         CLINICAL RESEARCH SERVICES TO DOMINATE MARKET DURING STUDY PERIOD            89

4.4         CRO SERVICES MARKET, BY END USER, 2023      89

FIGURE 19         PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2023     89

4.5         GEOGRAPHICAL GROWTH OPPORTUNITIES IN CRO SERVICES MARKET            90

FIGURE 20         ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD       90

5            MARKET OVERVIEW     91

5.1         INTRODUCTION            91

5.2         MARKET DYNAMICS     91

FIGURE 21         DRIVERS, OPPORTUNITIES, AND CHALLENGES: CRO SERVICES MARKET            91

TABLE 4             IMPACT ANALYSIS: CRO SERVICES MARKET      92

5.2.1      DRIVERS            92

5.2.1.1   Rising pharmaceutical R&D expenditure and increasing drug pipeline     92

FIGURE 22         LARGE PHARMACEUTICAL R&D SPENDING (AS A PERCENTAGE OF SALES), 2013–2022       93

FIGURE 23         ACTIVE PHARMACEUTICAL PIPELINE, 2012–2023            94

5.2.1.2   Technological advancements in clinical trials and innovative trial designs 94

5.2.1.3   High cost of in-house drug development        96

5.2.2      OPPORTUNITIES           96

5.2.2.1   Favorable growth prospects for biologics and biosimilars market 96

FIGURE 24         BIOSIMILARS APPROVALS AND LAUNCHES, 2015–2022  97

5.2.2.2   Need for novel clinical trial designs for complex cell & gene therapies      97

FIGURE 25         ONGOING CLINICAL TRIALS BY PHASE AND THERAPEUTIC APPROACH  (AS OF APRIL 2023)            98

FIGURE 26         GENE & CELL THERAPY DEVELOPERS, CLINICAL TRIALS, AND INVESTMENT,  BY REGION, 2022           98

5.2.2.3   Emergence of hybrid models with CRO-CDMO partnerships    99

5.2.2.4   Growing focus on personalized/precision medicine     99

5.2.2.5   Development of next-generation biotherapeutic products          99

5.2.3      CHALLENGES   100

5.2.3.1   Lack of adequate patient recruitment and retention for clinical trials        100

5.2.3.2   Changing clinical trial complexities  101

5.3         MARKET TRENDS          101

5.3.1      INDUSTRY CONSOLIDATION    101

TABLE 5             LIST OF MERGERS AND ACQUISITIONS 102

5.3.2      DECENTRALIZED CLINICAL TRIALS      102

5.3.3      REAL-WORLD DATA AND REAL-WORLD EVIDENCE       103

5.3.4      INCREASING INVOLVEMENT OF ARTIFICIAL INTELLIGENCE     103

5.4         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 103

FIGURE 27         REVENUE SHIFT AND NEW POCKETS FOR CRO SERVICE PROVIDERS       104

5.5         PRICING ANALYSIS        104

TABLE 6             PRICING ILLUSTRATION FOR FIRST IN-HUMAN TRIAL IN HEALTHY VOLUNTEERS IN EUROPE     105

5.6         VALUE CHAIN ANALYSIS            106

FIGURE 28         VALUE CHAIN ANALYSIS: CLINICAL RESEARCH TO ADD MAXIMUM VALUE         106

5.7         ECOSYSTEM ANALYSIS 107

TABLE 7             ROLE IN ECOSYSTEM: CRO SERVICES MARKET 107

5.8         TECHNOLOGY ANALYSIS           108

5.9         CASE STUDY ANALYSIS 109

5.9.1      PPD TO LEVERAGE ITS PRECLARUS TECHNOLOGY FOR GENERATING CLEANER DATA, FASTER CLINICAL TRIALS, AND LESSER SITE BURDEN 109

5.9.2      IQVIA TO OFFER AI-POWERED MODELING FOR BETTER PATIENT IDENTIFICATION           110

5.9.3      USE OF LAB DATA INSIGHTS TO IMPROVE POPULATION MANAGEMENT OF CHRONIC KIDNEY DISEASES             110

5.9.4      IQVIA TO LEVERAGE ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR IMPROVED SERVICE OFFERINGS           110

5.10       KEY CONFERENCES & EVENTS  111

TABLE 8             DETAILED LIST OF KEY CONFERENCES & EVENTS, 2024 111

5.11       REGULATORY ANALYSIS            111

5.11.1    REGULATORY ANALYSIS            111

5.11.2    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          112

TABLE 9             NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         112

TABLE 10           EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 112

TABLE 11           ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         113

TABLE 12           REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         113

5.11.3    REGULATORY SCENARIO FOR DRUG APPROVALS AND CGMP PROCEDURES   114

5.12       PORTER’S FIVE FORCES ANALYSIS         117

TABLE 13           PORTER’S FIVE FORCES ANALYSIS: CRO SERVICES MARKET              117

5.12.1    THREAT OF NEW ENTRANTS    117

5.12.2    THREAT OF SUBSTITUTES         118

5.12.3    BARGAINING POWER OF BUYERS           118

5.12.4    BARGAINING POWER OF SUPPLIERS     118

5.12.5    INTENSITY OF COMPETITIVE RIVALRY 118

5.13       KEY STAKEHOLDERS & BUYING CRITERIA          119

5.13.1    KEY STAKEHOLDERS IN BUYING PROCESS         119

FIGURE 29         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CRO SERVICES IN PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES              119

5.13.2    BUYING CRITERIA         120

FIGURE 30         KEY BUYING CRITERIA FOR END USERS              120

6            CRO SERVICES MARKET, BY TYPE          122

6.1         INTRODUCTION            123

TABLE 14           CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)              123

6.2         CLINICAL RESEARCH SERVICES 123

TABLE 15           NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES, BY LOCATION (AS OF DECEMBER 21, 2023)     124

FIGURE 31         DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2022 VS. 2023              124

TABLE 16           EXAMPLES OF CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS         125

TABLE 17           CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)  126

TABLE 18           CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY REGION,  2022–2029 (USD MILLION)             126

TABLE 19           NORTH AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,  BY COUNTRY, 2022–2029 (USD MILLION)            126

TABLE 20           EUROPE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)       127

TABLE 21           ASIA PACIFIC: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY COUNTRY, 2022–2029 (USD MILLION) 127

TABLE 22           LATIN AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,  BY COUNTRY, 2022–2029 (USD MILLION)            128

TABLE 23           MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,  BY REGION, 2022–2029 (USD MILLION)              128

6.2.1      CLINICAL TRIAL SERVICES MARKET, BY PHASE 128

6.2.2      PHASE III CLINICAL RESEARCH SERVICES          129

6.2.2.1   Increased use of clinical resources and advanced technologies to drive segment              129

TABLE 24           EXAMPLES OF DRUGS IN PHASE III OF CLINICAL TRIALS, 2023              129

TABLE 25          PHASE III CLINICAL RESEARCH SERVICES MARKET, BY REGION,  2022–2029 (USD MILLION)          130

TABLE 26           NORTH AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)         130

TABLE 27           EUROPE: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         130

TABLE 28           ASIA PACIFIC: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      131

TABLE 29           LATIN AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      131

TABLE 30           MIDDLE EAST & AFRICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)        131

6.2.3      PHASE II CLINICAL RESEARCH SERVICES            132

6.2.3.1   Rising number of pipeline products to propel market   132

TABLE 31           EXAMPLES OF DRUGS IN PHASE II OF CLINICAL TRIALS, 2023              132

TABLE 32           PHASE II CLINICAL RESEARCH SERVICES MARKET, BY REGION,  2022–2029 (USD MILLION)          133

TABLE 33           NORTH AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)         133

TABLE 34           EUROPE: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 133

TABLE 35           ASIA PACIFIC: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      134

TABLE 36           LATIN AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      134

TABLE 37           MIDDLE EAST & AFRICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)        134

6.2.4      PHASE I CLINICAL RESEARCH SERVICES             135

6.2.4.1   Growing R&D pipeline of pharmaceutical companies to support segment 135

TABLE 38           EXAMPLES OF DRUGS IN PHASE I OF CLINICAL TRIALS, 2023              135

TABLE 39           PHASE I CLINICAL RESEARCH SERVICES MARKET, BY REGION,  2022–2029 (USD MILLION)          136

TABLE 40           NORTH AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      136

TABLE 41           EUROPE: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 136

TABLE 42           ASIA PACIFIC: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      137

TABLE 43           LATIN AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      137

TABLE 44           MIDDLE EAST & AFRICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)        137

6.2.5      PHASE IV CLINICAL RESEARCH SERVICES          138

6.2.5.1   Increasing number of CROs providing post-marketing surveillance to drive segment 138

TABLE 45           EXAMPLES OF DRUGS IN PHASE IV OF CLINICAL TRIALS, 2023              138

TABLE 46          PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY REGION,  2022–2029 (USD MILLION)          139

TABLE 47           NORTH AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)         139

TABLE 48           EUROPE: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         139

TABLE 49           ASIA PACIFIC: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      140

TABLE 50           LATIN AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      140

TABLE 51           MIDDLE EAST & AFRICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)        140

6.2.6      CLINICAL RESEARCH SERVICES MARKET, BY STUDY DESIGN     141

TABLE 52           CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY STUDY DESIGN, 2022–2029 (USD MILLION)   141

TABLE 53           CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY REGION, 2022–2029 (USD MILLION)  141

6.2.6.1   Interventional studies        141

6.2.6.1.1 Better monitoring and data collection with structured protocol to propel segment              141

TABLE 54           INTERVENTIONAL STUDIES MARKET, BY REGION, 2022–2029 (USD MILLION) 142

6.2.6.2   Real world evidence studies              142

6.2.6.2.1 Increasing focus on informed healthcare decision-making to boost segment              142

TABLE 55           REAL WORLD EVIDENCE STUDIES MARKET, BY REGION, 2022–2029 (USD MILLION)     143

6.3         EARLY-PHASE DEVELOPMENT SERVICES           143

TABLE 56           EXAMPLES OF EARLY-PHASE DEVELOPMENT SERVICES OFFERED BY MARKET PLAYERS 143

TABLE 57           CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE,  2022–2029 (USD MILLION)             144

TABLE 58           CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY REGION,  2022–2029 (USD MILLION)        144

TABLE 59           NORTH AMERICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)      145

TABLE 60           EUROPE: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,  BY COUNTRY, 2022–2029 (USD MILLION)   145

TABLE 61           ASIA PACIFIC: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,  BY COUNTRY, 2022–2029 (USD MILLION)   146

TABLE 62           LATIN AMERICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)      146

TABLE 63           MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY REGION, 2022–2029 (USD MILLION)              146

6.3.1      CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES       147

6.3.1.1   Growing need to meet regulatory norms in drug development to drive segment              147

TABLE 64           CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES MARKET, BY REGION,  2022–2029 (USD MILLION)          147

TABLE 65           NORTH AMERICA: CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)              147

TABLE 66           EUROPE: CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)  148

TABLE 67           ASIA PACIFIC: CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)  148

TABLE 68           LATIN AMERICA: CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)              149

TABLE 69           MIDDLE EAST & AFRICA: CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)   149

6.3.2      PRECLINICAL SERVICES             149

TABLE 70           PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          150

TABLE 71           PRECLINICAL SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)          150

TABLE 72           NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 151

TABLE 73           EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          151

TABLE 74           ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)          152

TABLE 75           LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 152

TABLE 76           MIDDLE EAST & AFRICA: PRECLINICAL SERVICES MARKET, BY REGION,  2022–2029 (USD MILLION)     152

6.3.2.1   Pharmacokinetics/Pharmacodynamics           153

6.3.2.1.1 High significance of drug metabolism studies to drive segment  153

TABLE 77           PHARMACOKINETICS/PHARMACODYNAMICS MARKET, BY REGION,  2022–2029 (USD MILLION)     153

TABLE 78           NORTH AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)     154

TABLE 79           EUROPE: PHARMACOKINETICS/PHARMACODYNAMICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)         154

TABLE 80           ASIA PACIFIC: PHARMACOKINETICS/PHARMACODYNAMICS MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)      155

TABLE 81           LATIN AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)     155

TABLE 82           MIDDLE EAST & AFRICA: PHARMACOKINETICS/PHARMACODYNAMICS MARKET, BY REGION, 2022–2029 (USD MILLION) 155

6.3.2.2   Toxicology testing              156

6.3.2.2.1 Growing need to provide high-quality and safe drugs to drive segment     156

TABLE 83           TOXICOLOGY TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)          156

TABLE 84           NORTH AMERICA: TOXICOLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 157

TABLE 85           EUROPE: TOXICOLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)          157

TABLE 86           ASIA PACIFIC: TOXICOLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)          158

TABLE 87           LATIN AMERICA: TOXICOLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 158

TABLE 88           MIDDLE EAST & AFRICA: TOXICOLOGY TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)       158

6.3.2.3   Other preclinical services   159

TABLE 89           OTHER PRECLINICAL SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)     159

TABLE 90           NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         159

TABLE 91           EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 160

TABLE 92           ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 160

TABLE 93           LATIN AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 161

TABLE 94           MIDDLE EAST & AFRICA: OTHER PRECLINICAL SERVICES MARKET, BY REGION,  2022–2029 (USD MILLION)          161

6.3.3      DISCOVERY STUDIES    161

6.3.3.1   Increasing reliance on CRO services for target identification and validation to propel segment    161

TABLE 95           DISCOVERY STUDIES MARKET, BY REGION, 2022–2029 (USD MILLION)          162

TABLE 96           NORTH AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 162

TABLE 97           EUROPE: DISCOVERY STUDIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     162

TABLE 98           ASIA PACIFIC: DISCOVERY STUDIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          163

TABLE 99           LATIN AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          163

TABLE 100         MIDDLE EAST & AFRICA: DISCOVERY STUDIES MARKET, BY REGION,  2022–2029 (USD MILLION)     163

6.4         LABORATORY SERVICES            164

TABLE 101         EXAMPLES OF LABORATORY SERVICES OFFERED BY MARKET PLAYERS           164

TABLE 102        CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)          165

TABLE 103         CRO SERVICES MARKET FOR LABORATORY SERVICES, BY REGION,  2022–2029 (USD MILLION)     165

TABLE 104         NORTH AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)       165

TABLE 105        EUROPE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY COUNTRY,  2022–2029 (USD MILLION)         166

TABLE 106         ASIA PACIFIC: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY COUNTRY,  2022–2029 (USD MILLION)    166

TABLE 107         LATIN AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)       167

TABLE 108         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR LABORATORY SERVICES,  BY REGION, 2022–2029 (USD MILLION)          167

6.4.1      ANALYTICAL TESTING 167

TABLE 109         ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)          168

TABLE 110         ANALYTICAL TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)          168

TABLE 111         NORTH AMERICA: ANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 168

TABLE 112         EUROPE: ANALYTICAL TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     169

TABLE 113        ASIA PACIFIC: ANALYTICAL TESTING  MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          169

TABLE 114         LATIN AMERICA: ANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 170

TABLE 115         MIDDLE EAST & AFRICA: ANALYTICAL TESTING MARKET, BY REGION,  2022–2029 (USD MILLION)     170

6.4.1.1   Physical characterization   170

6.4.1.1.1 Growing need to reduce risk of product failures to drive segment             170

TABLE 116         PHYSICAL CHARACTERIZATION MARKET, BY REGION,  2022–2029 (USD MILLION)     171

TABLE 117         NORTH AMERICA: PHYSICAL CHARACTERIZATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)            171

TABLE 118         EUROPE: PHYSICAL CHARACTERIZATION MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 171

TABLE 119         ASIA PACIFIC: PHYSICAL CHARACTERIZATION MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 172

TABLE 120         LATIN AMERICA: PHYSICAL CHARACTERIZATION MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 172

TABLE 121         MIDDLE EAST & AFRICA: PHYSICAL CHARACTERIZATION MARKET, BY REGION, 2022–2029 (USD MILLION)            172

6.4.1.2   Raw material testing          173

6.4.1.2.1 Importance of quality and purity of raw materials to propel segment        173

TABLE 122         RAW MATERIAL TESTING MARKET, BY REGION, 2022–2029 (USD MILLION) 173

TABLE 123         NORTH AMERICA: RAW MATERIAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 173

TABLE 124         EUROPE: RAW MATERIAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)          174

TABLE 125         ASIA PACIFIC: RAW MATERIAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 174

TABLE 126         LATIN AMERICA: RAW MATERIAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 175

TABLE 127         MIDDLE EAST & AFRICA: RAW MATERIAL TESTING MARKET, BY REGION,  2022–2029 (USD MILLION)             175

6.4.1.3   Batch-release testing          175

6.4.1.3.1 Wide range of batch-release testing services offered by CROs to propel growth              175

TABLE 128         BATCH-RELEASE TESTING MARKET, BY REGION, 2022–2029 (USD MILLION) 176

TABLE 129         NORTH AMERICA: BATCH-RELEASE TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 176

TABLE 130         EUROPE: BATCH-RELEASE TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)          176

TABLE 131         ASIA PACIFIC: BATCH-RELEASE TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 177

TABLE 132         LATIN AMERICA: BATCH-RELEASE TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 177

TABLE 133         MIDDLE EAST & AFRICA: BATCH-RELEASE TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)  177

6.4.1.4   Stability testing    178

6.4.1.4.1 Long-term quality, safety, and efficacy of pharmaceutical products to drive segment 178

TABLE 134         STABILITY TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)          178

TABLE 135        NORTH AMERICA: STABILITY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)          179

TABLE 136         EUROPE: STABILITY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)     179

TABLE 137         ASIA PACIFIC: STABILITY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)          180

TABLE 138         LATIN AMERICA: STABILITY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)          180

TABLE 139         MIDDLE EAST & AFRICA: STABILITY TESTING MARKET, BY REGION,  2022–2029 (USD MILLION)     180

6.4.1.5   Other analytical testing      181

TABLE 140         OTHER ANALYTICAL TESTING MARKET, BY REGION, 2022–2029 (USD MILLION) 181

TABLE 141         NORTH AMERICA: OTHER ANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 181

TABLE 142         EUROPE: OTHER ANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 182

TABLE 143         ASIA PACIFIC: OTHER ANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 182

TABLE 144         LATIN AMERICA: OTHER ANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 183

TABLE 145         MIDDLE EAST & AFRICA: OTHER ANALYTICAL TESTING MARKET, BY REGION,  2022–2029 (USD MILLION)          183

6.4.2      BIOANALYTICAL TESTING        183

6.4.2.1   Rising significance of accurate PK/PD studies to drive segment 183

TABLE 146         BIOANALYTICAL TESTING MARKET, BY REGION, 2022–2029 (USD MILLION) 184

TABLE 147         NORTH AMERICA: BIOANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 184

TABLE 148         EUROPE: BIOANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)          185

TABLE 149         ASIA PACIFIC: BIOANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 185

TABLE 150         LATIN AMERICA: BIOANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 186

TABLE 151         MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING MARKET, BY REGION,  2022–2029 (USD MILLION)             186

6.5         CONSULTING SERVICES             186

6.5.1      GROWING ADOPTION OF CONSULTING SERVICES FOR FASTER REGULATORY APPROVALS TO SUPPORT MARKET         186

TABLE 152         EXAMPLES OF CONSULTING SERVICES OFFERED BY MARKET PLAYERS           187

TABLE 153         CRO SERVICES MARKET FOR CONSULTING SERVICES, BY REGION,  2022–2029 (USD MILLION)     188

TABLE 154         NORTH AMERICA: CRO SERVICES MARKET FOR CONSULTING SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)       188

TABLE 155        EUROPE: CRO SERVICES MARKET FOR CONSULTING SERVICES, BY COUNTRY,  2022–2029 (USD MILLION)         189

TABLE 156         ASIA PACIFIC: CRO SERVICES MARKET FOR CONSULTING SERVICES, BY COUNTRY,  2022–2029 (USD MILLION)    189

TABLE 157         LATIN AMERICA: CRO SERVICES MARKET FOR CONSULTING SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)       190

TABLE 158         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR CONSULTING SERVICES,  BY REGION, 2022–2029 (USD MILLION)           190

6.6         DATA MANAGEMENT SERVICES             190

6.6.1      DATA MANAGEMENT SERVICES TO COMMAND HIGHEST GROWTH RATE DURING FORECAST PERIOD         190

TABLE 159         EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY MARKET PLAYERS         191

TABLE 160         CRO SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY REGION,  2022–2029 (USD MILLION)             191

TABLE 161         NORTH AMERICA: CRO SERVICES MARKET FOR DATA MANAGEMENT SERVICES,  BY COUNTRY, 2022–2029 (USD MILLION)    192

TABLE 162         EUROPE: CRO SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)       192

TABLE 163         ASIA PACIFIC: CRO SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)       193

TABLE 164         LATIN AMERICA: CRO SERVICES MARKET FOR DATA MANAGEMENT SERVICES,  BY COUNTRY, 2022–2029 (USD MILLION)    193

TABLE 165         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR DATA MANAGEMENT SERVICES,  BY REGION, 2022–2029 (USD MILLION)        193

7            CRO SERVICES MARKET, BY THERAPEUTIC AREA           194

7.1         INTRODUCTION            195

TABLE 166         CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 195

7.2         ONCOLOGY      196

TABLE 167         NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040              196

FIGURE 32         NUMBER OF REGISTERED ONCOLOGY CLINICAL TRIALS,  2012–2023 (THOUSAND)             197

TABLE 168         LIST OF FDA DRUGS APPROVED FOR ONCOLOGY, 2023 197

TABLE 169         CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION) 198

TABLE 170         CRO SERVICES MARKET FOR ONCOLOGY, BY REGION, 2022–2029 (USD MILLION)     198

TABLE 171         NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)         199

TABLE 172         EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,  2022–2029 (USD MILLION) 199

TABLE 173         ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,  2022–2029 (USD MILLION) 200

TABLE 174         LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,  2022–2029 (USD MILLION) 200

TABLE 175         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR ONCOLOGY, BY REGION,  2022–2029 (USD MILLION)    200

7.2.1      BREAST CANCER            201

7.2.1.1   Strong R&D pipeline for breast cancer drugs to drive segment   201

TABLE 176         BREAST CANCER MARKET, BY REGION, 2022–2029 (USD MILLION)          201

TABLE 177         NORTH AMERICA: BREAST CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          202

TABLE 178         EUROPE: BREAST CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 202

TABLE 179         ASIA PACIFIC: BREAST CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     202

TABLE 180         LATIN AMERICA: BREAST CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          203

TABLE 181         MIDDLE EAST & AFRICA: BREAST CANCER MARKET, BY REGION,  2022–2029 (USD MILLION)     203

7.2.2      LUNG CANCER 203

7.2.2.1   Increasing focus on research for advanced treatment to drive segment     203

TABLE 182         LUNG CANCER MARKET, BY REGION, 2022–2029 (USD MILLION)          204

TABLE 183         NORTH AMERICA: LUNG CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          204

TABLE 184         EUROPE: LUNG CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 204

TABLE 185         ASIA PACIFIC: LUNG CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     205

TABLE 186         LATIN AMERICA: LUNG CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     205

TABLE 187         MIDDLE EAST & AFRICA: LUNG CANCER MARKET, BY REGION,  2022–2029 (USD MILLION)          205

7.2.3      PROSTATE CANCER      206

7.2.3.1   Rising number of research initiatives to propel market 206

TABLE 188         PROSTATE CANCER MARKET, BY REGION, 2022–2029 (USD MILLION)          206

TABLE 189         NORTH AMERICA: PROSTATE CANCER MARKET, BY COUNTRY,  2022–2029 (USD MILLION)          207

TABLE 190         EUROPE: PROSTATE CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     207

TABLE 191         ASIA PACIFIC: PROSTATE CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          207

TABLE 192         LATIN AMERICA: PROSTATE CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          208

TABLE 193         MIDDLE EAST & AFRICA: PROSTRATE CANCER MARKET, BY REGION,  2022–2029 (USD MILLION)     208

7.2.4      COLORECTAL CANCER 208

7.2.4.1   Increasing drug research activities to support market   208

TABLE 194         COLORECTAL CANCER MARKET, BY REGION, 2022–2029 (USD MILLION)          209

TABLE 195         NORTH AMERICA: COLORECTAL CANCER MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 209

TABLE 196         EUROPE: COLORECTAL CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     210

TABLE 197         ASIA PACIFIC: COLORECTAL CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          210

TABLE 198         LATIN AMERICA: COLORECTAL CANCER MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 211

TABLE 199         MIDDLE EAST & AFRICA: COLORECTAL CANCER MARKET, BY REGION,  2022–2029 (USD MILLION)     211

7.2.5      OTHER CANCERS           211

TABLE 200         NUMBER OF DRUGS IN R&D PIPELINE FOR OTHER CANCERS, 2022 AND 2023  212

TABLE 201         OTHER CANCERS MARKET, BY REGION, 2022–2029 (USD MILLION)          212

TABLE 202         NORTH AMERICA: OTHER CANCERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          212

TABLE 203         EUROPE: OTHER CANCERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 213

TABLE 204         ASIA PACIFIC: OTHER CANCERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     213

TABLE 205         LATIN AMERICA: OTHER CANCERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          214

TABLE 206         MIDDLE EAST & AFRICA: OTHER CANCERS MARKET, BY REGION,  2022–2029 (USD MILLION)     214

7.3         INFECTIOUS DISEASES 214

7.3.1      GROWING INCIDENCE OF CHRONIC INFECTIONS TO SUPPORT MARKET            214

TABLE 207         CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION,  2022–2029 (USD MILLION)     215

TABLE 208         NORTH AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)       215

TABLE 209         EUROPE: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,  2022–2029 (USD MILLION)         216

TABLE 210         ASIA PACIFIC: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,  2022–2029 (USD MILLION)     216

TABLE 211         LATIN AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)       217

TABLE 212         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES,  BY REGION, 2022–2029 (USD MILLION)             217

7.4         CARDIOVASCULAR SYSTEM DISORDERS            217

7.4.1      INCREASING PREVALENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET            217

TABLE 213         EXAMPLES OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES  (AS OF DECEMBER 2023)      218

TABLE 214         CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2022–2029 (USD MILLION)       219

TABLE 215         NORTH AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)          219

TABLE 216         EUROPE: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS,  BY COUNTRY, 2022–2029 (USD MILLION)             219

TABLE 217         ASIA PACIFIC: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS,  BY COUNTRY, 2022–2029 (USD MILLION)             220

TABLE 218         LATIN AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)          220

TABLE 219         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2022–2029 (USD MILLION)          220

7.5         NEUROLOGY    221

7.5.1      INCREASING INVESTMENTS IN R&D TO DRIVE MARKET             221

TABLE 220         CRO SERVICES MARKET FOR NEUROLOGY, BY REGION, 2022–2029 (USD MILLION)     222

TABLE 221         NORTH AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY,  2022–2029 (USD MILLION)         222

TABLE 222         EUROPE: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY,  2022–2029 (USD MILLION) 222

TABLE 223         ASIA PACIFIC: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY,  2022–2029 (USD MILLION) 223

TABLE 224         LATIN AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY,  2022–2029 (USD MILLION)         223

TABLE 225         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR NEUROLOGY, BY REGION,  2022–2029 (USD MILLION)  223

7.6         METABOLIC DISORDERS/ENDOCRINOLOGY     224

7.6.1      INCREASING NUMBER OF DIABETES PATIENTS TO BOOST MARKET              224

FIGURE 33         ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES,  2000–2045 (MILLION)    224

TABLE 226         CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2022–2029 (USD MILLION) 225

TABLE 227         NORTH AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)              225

TABLE 228         EUROPE: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY,  BY COUNTRY, 2022–2029 (USD MILLION)              226

TABLE 229         ASIA PACIFIC: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)              226

TABLE 230         LATIN AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)              227

TABLE 231         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2022–2029 (USD MILLION)          227

7.7         IMMUNOLOGICAL DISORDERS 227

7.7.1      GROWING CLINICAL RESEARCH AND RISING NUMBER OF DRUGS IN R&D PIPELINE TO DRIVE MARKET         227

TABLE 232         EXAMPLES OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS, 2023           228

TABLE 233         CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION,  2022–2029 (USD MILLION)             228

TABLE 234         NORTH AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS,  BY COUNTRY, 2022–2029 (USD MILLION)              228

TABLE 235         EUROPE: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)   229

TABLE 236         ASIA PACIFIC: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)   229

TABLE 237         LATIN AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS,  BY COUNTRY, 2022–2029 (USD MILLION)              230

TABLE 238         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS,  BY REGION, 2022–2029 (USD MILLION)              230

7.8         VACCINES         230

7.8.1      GROWING PREVALENCE OF INFECTIOUS DISEASES AND RISING GOVERNMENT FUNDING TO SUPPORT MARKET           230

TABLE 239         CRO SERVICES MARKET FOR VACCINES, BY REGION, 2022–2029 (USD MILLION) 231

TABLE 240         NORTH AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,  2022–2029 (USD MILLION) 231

TABLE 241         EUROPE: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,  2022–2029 (USD MILLION) 231

TABLE 242         ASIA PACIFIC: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,  2022–2029 (USD MILLION) 232

TABLE 243         LATIN AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,  2022–2029 (USD MILLION) 232

TABLE 244         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR VACCINES, BY REGION,  2022–2029 (USD MILLION)       232

7.9         PSYCHIATRY    233

7.9.1      GROWING CASES OF PSYCHIATRIC DISORDERS AND INCREASING INVESTMENT IN R&D TO DRIVE MARKET          233

TABLE 245         CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2022–2029 (USD MILLION)     233

TABLE 246         NORTH AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,  2022–2029 (USD MILLION)         234

TABLE 247         EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,  2022–2029 (USD MILLION) 234

TABLE 248         ASIA PACIFIC: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,  2022–2029 (USD MILLION) 235

TABLE 249         LATIN AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,  2022–2029 (USD MILLION) 235

TABLE 250         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION,  2022–2029 (USD MILLION)  235

7.10       RESPIRATORY DISORDERS        236

7.10.1    RISING INCIDENCE OF UNDIAGNOSED RESPIRATORY DISORDERS AMONG CHILDREN TO PROPEL MARKET          236

TABLE 251         LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES, 2023              236

TABLE 252         CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION,  2022–2029 (USD MILLION)     237

TABLE 253         NORTH AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)   237

TABLE 254         EUROPE: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY,  2022–2029 (USD MILLION) 237

TABLE 255         ASIA PACIFIC: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)   238

TABLE 256         LATIN AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)   238

TABLE 257         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS,  BY REGION, 2022–2029 (USD MILLION)      238

7.11       DERMATOLOGY            239

7.11.1    GROWING FOCUS ON DRUG DEVELOPMENT AGAINST VARIOUS SKIN CONDITIONS TO SUPPORT MARKET    239

TABLE 258         LIST OF PIPELINE DRUGS FOR SKIN DISEASES, 2023       239

TABLE 259         CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION, 2022–2029 (USD MILLION)          240

TABLE 260         NORTH AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)      240

TABLE 261         EUROPE: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY,  2022–2029 (USD MILLION) 240

TABLE 262         ASIA PACIFIC: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)         241

TABLE 263        LATIN AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)         241

TABLE 264         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION, 2022–2029 (USD MILLION)             241

7.12       OPHTHALMOLOGY      242

7.12.1    RISING NUMBER OF PIPELINE DRUGS AND GROWING FOCUS ON R&D TO DRIVE MARKET       242

TABLE 265         CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION, 2022–2029 (USD MILLION)          242

TABLE 266         NORTH AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY,  2022–2029 (USD MILLION) 242

TABLE 267         EUROPE: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY,  2022–2029 (USD MILLION) 243

TABLE 268         ASIA PACIFIC: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY,  2022–2029 (USD MILLION) 243

TABLE 269         LATIN AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY,  2022–2029 (USD MILLION) 244

TABLE 270         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION, 2022–2029 (USD MILLION)       244

7.13       GASTROINTESTINAL DISEASES 244

7.13.1    INCREASING LEVELS OF OBESITY WITH LIFESTYLE AND DIETARY CHANGES TO DRIVE MARKET   244

TABLE 271         CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION,  2022–2029 (USD MILLION)             245

TABLE 272         NORTH AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES,  BY COUNTRY, 2022–2029 (USD MILLION)              245

TABLE 273         EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)       245

TABLE 274         ASIA PACIFIC: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)              246

TABLE 275         LATIN AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES,  BY COUNTRY, 2022–2029 (USD MILLION)              246

TABLE 276         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES,  BY REGION, 2022–2029 (USD MILLION)              246

7.14       GENITOURINARY & WOMEN’S HEALTH 247

7.14.1    RISING PREVALENCE OF CHRONIC DISORDERS AND INCREASING NUMBER OF PIPELINE DRUGS TO PROPEL MARKET      247

TABLE 277         CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION,  2022–2029 (USD MILLION)          247

TABLE 278         NORTH AMERICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH,  BY COUNTRY, 2022–2029 (USD MILLION)          248

TABLE 279         EUROPE: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH,  BY COUNTRY, 2022–2029 (USD MILLION)  248

TABLE 280         ASIA PACIFIC: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH,  BY COUNTRY, 2022–2029 (USD MILLION)  249

TABLE 281         LATIN AMERICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH,  BY COUNTRY, 2022–2029 (USD MILLION)          249

TABLE 282         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2022–2029 (USD MILLION)              249

7.15       HEMATOLOGY 250

7.15.1    GROWING PREVALENCE OF BLOOD-RELATED DISEASES TO SUPPORT MARKET            250

TABLE 283         CRO SERVICES MARKET FOR HEMATOLOGY, BY REGION, 2022–2029 (USD MILLION)     250

TABLE 284        NORTH AMERICA: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)         251

TABLE 285         EUROPE: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY,  2022–2029 (USD MILLION) 251

TABLE 286         ASIA PACIFIC: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY,  2022–2029 (USD MILLION) 252

TABLE 287         LATIN AMERICA: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)         252

TABLE 288         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR HEMATOLOGY, BY REGION,  2022–2029 (USD MILLION)             252

7.16       OTHER THERAPEUTIC AREAS   253

TABLE 289         CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION,  2022–2029 (USD MILLION)     253

TABLE 290         NORTH AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,  BY COUNTRY, 2022–2029 (USD MILLION)           253

TABLE 291         EUROPE: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY,  2022–2029 (USD MILLION)          254

TABLE 292         ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)             254

TABLE 293         LATIN AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)             255

TABLE 294         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,  BY REGION, 2022–2029 (USD MILLION) 255

7.17       CUSTOMIZATION          255

7.17.1    CELL & GENE THERAPY 255

7.17.1.1 Growing investments for advanced research initiatives to support market 255

TABLE 295         CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION,  2022–2029 (USD MILLION)     257

TABLE 296         NORTH AMERICA: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022–2029 (USD MILLION)       257

TABLE 297         EUROPE: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY,  2022–2029 (USD MILLION)         257

TABLE 298         ASIA PACIFIC: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY,  2022–2029 (USD MILLION)    258

TABLE 299         LATIN AMERICA: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022–2029 (USD MILLION)       258

TABLE 300         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR CELL & GENE THERAPY,  BY REGION, 2022–2029 (USD MILLION)           258

7.17.2    RARE DISEASES 259

7.17.2.1 Rising number of R&D activities for rare disease treatment to drive market              259

TABLE 301         CRO SERVICES MARKET FOR RARE DISEASES, BY REGION, 2022–2029 (USD MILLION)     259

TABLE 302         NORTH AMERICA: CRO SERVICES MARKET FOR RARE DISEASES, BY COUNTRY,  2022–2029 (USD MILLION)     260

TABLE 303         EUROPE: CRO SERVICES MARKET FOR RARE DISEASES, BY COUNTRY,  2022–2029 (USD MILLION) 260

TABLE 304         ASIA PACIFIC: CRO SERVICES MARKET FOR RARE DISEASES, BY COUNTRY,  2022–2029 (USD MILLION) 261

TABLE 305         LATIN AMERICA: CRO SERVICES MARKET FOR RARE DISEASES, BY COUNTRY,  2022–2029 (USD MILLION)         261

TABLE 306         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR RARE DISEASES, BY REGION, 2022–2029 (USD MILLION)           261

7.17.3    BIOSIMILARS    262

7.17.3.1 Growing focus on biosimilars and patent expiration of biologics to drive market              262

TABLE 307         CRO SERVICES MARKET FOR BIOSIMILARS, BY REGION, 2022–2029 (USD MILLION)     262

TABLE 308         NORTH AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY,  2022–2029 (USD MILLION)         263

TABLE 309         EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY,  2022–2029 (USD MILLION) 263

TABLE 310         ASIA PACIFIC: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY,  2022–2029 (USD MILLION) 264

TABLE 311         LATIN AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY,  2022–2029 (USD MILLION)         264

TABLE 312         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY REGION,  2022–2029 (USD MILLION)  264

TABLE 313         CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2022–2029 (USD MILLION) 265

7.17.3.2 Monoclonal antibodies      265

TABLE 314         MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION) 265

TABLE 315         NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 266

TABLE 316         EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          266

TABLE 317         ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 267

TABLE 318         LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 267

TABLE 319         MIDDLE EAST & AFRICA: MONOCLONAL ANTIBODIES MARKET, BY REGION,  2022–2029 (USD MILLION)          267

7.17.3.3 Insulin   268

TABLE 320         INSULIN MARKET, BY REGION, 2022–2029 (USD MILLION)              268

TABLE 321         NORTH AMERICA: INSULIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 268

TABLE 322         EUROPE: INSULIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          268

TABLE 323         ASIA PACIFIC: INSULIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          269

TABLE 324         LATIN AMERICA: INSULIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 269

TABLE 325         MIDDLE EAST & AFRICA: INSULIN MARKET, BY REGION, 2022–2029 (USD MILLION)     269

7.17.3.4 CSF       270

TABLE 326         CSF MARKET, BY REGION, 2022–2029 (USD MILLION)     270

TABLE 327         NORTH AMERICA: CSF MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          270

TABLE 328         EUROPE: CSF MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          270

TABLE 329         ASIA PACIFIC: CSF MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          271

TABLE 330         LATIN AMERICA: CSF MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          271

TABLE 331         MIDDLE EAST & AFRICA: CSF MARKET, BY REGION, 2022–2029 (USD MILLION) 271

7.17.3.5 Erythropoietin     272

TABLE 332         ERYTHROPOIETIN MARKET, BY REGION, 2022–2029 (USD MILLION)          272

TABLE 333         NORTH AMERICA: ERYTHROPOIETIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          272

TABLE 334         EUROPE: ERYTHROPOIETIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 272

TABLE 335         ASIA PACIFIC: ERYTHROPOIETIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          273

TABLE 336         LATIN AMERICA: ERYTHROPOIETIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          273

TABLE 337         MIDDLE EAST & AFRICA: ERYTHROPOIETIN MARKET, BY REGION,  2022–2029 (USD MILLION)     273

7.17.3.6 Other biosimilars 274

TABLE 338         OTHER BIOSIMILARS MARKET, BY REGION, 2022–2029 (USD MILLION)          274

TABLE 339         NORTH AMERICA: OTHER BIOSIMILARS MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 274

TABLE 340         EUROPE: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     274

TABLE 341         ASIA PACIFIC: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          275

TABLE 342         LATIN AMERICA: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          275

TABLE 343         MIDDLE EAST & AFRICA: OTHER BIOSIMILARS MARKET, BY REGION,  2022–2029 (USD MILLION)     275

8            CRO SERVICES MARKET, BY END USER  276

8.1         INTRODUCTION            277

TABLE 344         CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)          277

8.2         PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES   278

8.2.1      STABLE R&D PIPELINES AND INCREASED INVESTMENTS TO DRIVE MARKET            278

FIGURE 34         ANNUAL DRUG APPROVALS, BY CDER (FDA), 2012–2023 278

FIGURE 35         R&D SPENDING OF PHARMACEUTICAL MEMBER COMPANIES, 2012–2022          279

TABLE 345         CRO SERVICES MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)              280

TABLE 346         NORTH AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)          280

TABLE 347         EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)          281

TABLE 348         ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)          281

TABLE 349         LATIN AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)          282

TABLE 350         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)          282

8.3         MEDICAL DEVICE COMPANIES 282

8.3.1      INCREASING NUMBER OF GROWTH INITIATIVES BY MEDTECH ORGANIZATIONS TO DRIVE MARKET   282

FIGURE 36         US FDA DE NOVO MEDICAL DEVICE APPROVALS (2012–2023)              283

TABLE 351         CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION,  2022–2029 (USD MILLION)             284

TABLE 352         NORTH AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES,  BY COUNTRY, 2022–2029 (USD MILLION)             284

TABLE 353         EUROPE: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)  284

TABLE 354         ASIA PACIFIC: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)  285

TABLE 355         LATIN AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES,  BY COUNTRY, 2022–2029 (USD MILLION)             285

TABLE 356         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES,  BY REGION, 2022–2029 (USD MILLION)              285

8.4         ACADEMIC INSTITUTES             286

8.4.1      RISING NUMBER OF COLLABORATIONS BETWEEN CONTRACT RESEARCH ORGANIZATIONS AND ACADEMIA TO DRIVE MARKET         286

TABLE 357         CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION,  2022–2029 (USD MILLION)     287

TABLE 358         NORTH AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)  287

TABLE 359        EUROPE: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY,  2022–2029 (USD MILLION)         287

TABLE 360         ASIA PACIFIC: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY,  2022–2029 (USD MILLION) 288

TABLE 361         LATIN AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)  288

TABLE 362         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES,  BY REGION, 2022–2029 (USD MILLION)           288

9            CRO SERVICES MARKET, BY REGION     289

9.1         INTRODUCTION            290

TABLE 363         CRO SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)              290

9.2         NORTH AMERICA          290

FIGURE 37         NORTH AMERICA: CRO SERVICES MARKET SNAPSHOT 291

TABLE 364         NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          292

TABLE 365         NORTH AMERICA: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 292

TABLE 366         NORTH AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,  BY PHASE, 2022–2029 (USD MILLION)     292

TABLE 367         NORTH AMERICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION) 293

TABLE 368         NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          293

TABLE 369         NORTH AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)             293

TABLE 370         NORTH AMERICA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)          294

TABLE 371         NORTH AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)          294

TABLE 372         NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)    295

TABLE 373         NORTH AMERICA: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)          295

9.2.1      NORTH AMERICA: RECESSION IMPACT 295

9.2.2      US         296

9.2.2.1   US to dominate North American CRO services market during forecast period              296

FIGURE 38         DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION  (JANUARY 2022 VS. JANUARY 2023)         297

TABLE 374         US: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          297

TABLE 375         US: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)           298

TABLE 376         US: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION) 298

TABLE 377         US: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          298

TABLE 378         US: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)          299

TABLE 379         US: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)          299

TABLE 380         US: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 300

TABLE 381         US: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)     300

TABLE 382         US: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)          301

9.2.3      CANADA            301

9.2.3.1   Short approval time and favorable government R&D investments to drive market              301

TABLE 383         CANADA: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          302

TABLE 384         CANADA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)           302

TABLE 385         CANADA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION) 303

TABLE 386         CANADA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)     303

TABLE 387         CANADA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)             303

TABLE 388         CANADA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION) 304

TABLE 389         CANADA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)          304

TABLE 390         CANADA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)          305

TABLE 391         CANADA: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION) 305

9.3         EUROPE             305

TABLE 392         EUROPE: CRO SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 306

TABLE 393         EUROPE: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          306

TABLE 394         EUROPE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)           307

TABLE 395         EUROPE: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION) 307

TABLE 396         EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 307

TABLE 397        EUROPE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)    308

TABLE 398         EUROPE: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION) 308

TABLE 399         EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)          309

TABLE 400         EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)          309

TABLE 401         EUROPE: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION) 310

9.3.1      EUROPE: RECESSION IMPACT   310

9.3.2      GERMANY         310

9.3.2.1   Growing R&D spending and favorable government policies to propel market              310

TABLE 402         GERMANY: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          311

TABLE 403         GERMANY: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION) 311

TABLE 404         GERMANY: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,  BY TYPE, 2022–2029 (USD MILLION)            312

TABLE 405         GERMANY: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)     312

TABLE 406         GERMANY: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)             312

TABLE 407         GERMANY: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)     313

TABLE 408         GERMANY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)          313

TABLE 409         GERMANY: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)          314

TABLE 410         GERMANY: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION) 314

9.3.3      UK         314

9.3.3.1   Growth in R&D expenditure in pharmaceutical industry to boost market 314

TABLE 411         UK: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          315

TABLE 412         UK: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)           316

TABLE 413         UK: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION) 316

TABLE 414         UK: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          316

TABLE 415         UK: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)          317

TABLE 416         UK: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)          317

TABLE 417         UK: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)     318

TABLE 418         UK: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)     318

TABLE 419         UK: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)          319

9.3.4      FRANCE             319

9.3.4.1   Government support for effective drug research to drive market growth  319

TABLE 420         FRANCE: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          320

TABLE 421         FRANCE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)           320

TABLE 422         FRANCE: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION) 321

TABLE 423         FRANCE: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 321

TABLE 424        FRANCE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)    321

TABLE 425         FRANCE: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION) 322

TABLE 426         FRANCE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)          322

TABLE 427         FRANCE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)          323

TABLE 428         FRANCE: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION) 323

9.3.5      ITALY   323

9.3.5.1   Increased availability of funding for drug discovery and development to drive market   323

TABLE 429         ITALY: NUMBER OF CLINICAL TRIALS IN ITALY, BY COMPANY (JANUARY 2022 VS. JANUARY 2023)         324

TABLE 430         ITALY: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          324

TABLE 431         ITALY: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)           325

TABLE 432         ITALY: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION) 325

TABLE 433         ITALY: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 325

TABLE 434         ITALY: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)    326

TABLE 435         ITALY: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION) 326

TABLE 436         ITALY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)     327

TABLE 437         ITALY: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)          327

TABLE 438         ITALY: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)          328

9.3.6      SPAIN   328

9.3.6.1   Growing R&D expenditure to boost market   328

TABLE 439         SPAIN: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          328

TABLE 440         SPAIN: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)           329

TABLE 441         SPAIN: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION) 329

TABLE 442         SPAIN: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 329

TABLE 443         SPAIN: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)    330

TABLE 444         SPAIN: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION) 330

TABLE 445         SPAIN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)     331

TABLE 446         SPAIN: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)          331

TABLE 447         SPAIN: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)          332

9.3.7      REST OF EUROPE           332

TABLE 448         REST OF EUROPE: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 333

TABLE 449         REST OF EUROPE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,  BY PHASE, 2022–2029 (USD MILLION)     333

TABLE 450         REST OF EUROPE: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION) 334

TABLE 451         REST OF EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          334

TABLE 452         REST OF EUROPE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)             334

TABLE 453         REST OF EUROPE: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)          335

TABLE 454         REST OF EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)          335

TABLE 455         REST OF EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)    336

TABLE 456         REST OF EUROPE: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)     336

9.4         ASIA PACIFIC    336

FIGURE 39         ASIA PACIFIC: CRO SERVICES MARKET SNAPSHOT         337

TABLE 457         ASIA PACIFIC: CRO SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     338

TABLE 458         ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 338

TABLE 459         ASIA PACIFIC: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)       339

TABLE 460         ASIA PACIFIC: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,  BY TYPE, 2022–2029 (USD MILLION)            339

TABLE 461         ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          339

TABLE 462         ASIA PACIFIC: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)             340

TABLE 463         ASIA PACIFIC: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)     340

TABLE 464         ASIA PACIFIC: CRO SERVICES MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)          341

TABLE 465         ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)          342

TABLE 466         ASIA PACIFIC: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)     342

9.4.1      ASIA PACIFIC: RECESSION IMPACT        342

9.4.2      CHINA  343

9.4.2.1   Low manufacturing cost and increased establishment of R&D centers to drive market   343

TABLE 467         CHINA: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          344

TABLE 468         CHINA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)           344

TABLE 469         CHINA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION) 345

TABLE 470         CHINA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 345

TABLE 471         CHINA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)    345

TABLE 472         CHINA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION) 346

TABLE 473         CHINA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)     346

TABLE 474         CHINA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)          347

TABLE 475         CHINA: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)          347

9.4.3      INDIA   347

9.4.3.1   Growth in pharmaceutical industry and favorable scenario for foreign direct investment to propel market            347

TABLE 476         INDIA: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          348

TABLE 477         INDIA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)           348

TABLE 478         INDIA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION) 349

TABLE 479         INDIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 349

TABLE 480         INDIA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)    349

TABLE 481         INDIA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION) 350

TABLE 482         INDIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)     350

TABLE 483         INDIA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)          351

TABLE 484         INDIA: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)          351

9.4.4      JAPAN  351

9.4.4.1   Decline in number of clinical trials to limit market       351

TABLE 485         JAPAN: TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA,  2020, 2022, AND 2023       352

TABLE 486         JAPAN: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          352

TABLE 487         JAPAN: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)           353

TABLE 488         JAPAN: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION) 353

TABLE 489         JAPAN: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 353

TABLE 490         JAPAN: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)    354

TABLE 491         JAPAN: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION) 354

TABLE 492         JAPAN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)     355

TABLE 493         JAPAN: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)          355

TABLE 494         JAPAN: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)          356

9.4.5      AUSTRALIA       356

9.4.5.1   Favorable tax incentives and cash rebates to pharmaceutical companies to support market   356

TABLE 495         AUSTRALIA: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          357

TABLE 496         AUSTRALIA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION) 357

TABLE 497         AUSTRALIA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,  BY TYPE, 2022–2029 (USD MILLION)            358

TABLE 498         AUSTRALIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)     358

TABLE 499         AUSTRALIA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)             358

TABLE 500         AUSTRALIA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)     359

TABLE 501         AUSTRALIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)          359

TABLE 502         AUSTRALIA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)          360

TABLE 503         AUSTRALIA: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION) 360

9.4.6      SOUTH KOREA 360

9.4.6.1   Favorable government initiatives for drug development to drive market   360

TABLE 504         SOUTH KOREA: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 361

TABLE 505         SOUTH KOREA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)       361

TABLE 506         SOUTH KOREA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,  BY TYPE, 2022–2029 (USD MILLION)            362

TABLE 507         SOUTH KOREA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          362

TABLE 508         SOUTH KOREA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)             362

TABLE 509         SOUTH KOREA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)          363

TABLE 510         SOUTH KOREA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)          363

TABLE 511         SOUTH KOREA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)          364

TABLE 512         SOUTH KOREA: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)     364

9.4.7      NEW ZEALAND 364

9.4.7.1   Rising number of key players and growing R&D activities to support market              364

TABLE 513         NEW ZEALAND: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 365

TABLE 514         NEW ZEALAND: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)       365

TABLE 515         NEW ZEALAND: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,  BY TYPE, 2022–2029 (USD MILLION)            366

TABLE 516         NEW ZEALAND: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          366

TABLE 517         NEW ZEALAND: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)             366

TABLE 518         NEW ZEALAND: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)          367

TABLE 519         NEW ZEALAND: CRO SERVICES MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)          367

TABLE 520         NEW ZEALAND: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)          368

TABLE 521         NEW ZEALAND: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)     368

9.4.8      REST OF ASIA PACIFIC  368

TABLE 522         REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)     369

TABLE 523         REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,  BY PHASE, 2022–2029 (USD MILLION)     369

TABLE 524         REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)  370

TABLE 525         REST OF ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY TYPE,  2022–2029 (USD MILLION)          370

TABLE 526         REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)    370

TABLE 527         REST OF ASIA PACIFIC: ANALYTICAL TESTING MARKET, BY TYPE,  2022–2029 (USD MILLION)          371

TABLE 528         REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)           371

TABLE 529         REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)         372

TABLE 530         REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY END USER,  2022–2029 (USD MILLION)          372

9.5         LATIN AMERICA             372

TABLE 531         LATIN AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     373

TABLE 532         LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 373

TABLE 533         LATIN AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)       374

TABLE 534         LATIN AMERICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION) 374

TABLE 535         LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          374

TABLE 536         LATIN AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)             375

TABLE 537         LATIN AMERICA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)          375

TABLE 538         LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)          376

TABLE 539         LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)          376

TABLE 540         LATIN AMERICA: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)     377

9.5.1      LATIN AMERICA: RECESSION IMPACT   377

9.5.2      BRAZIL 377

9.5.2.1   Increased government investments in pharmaceutical R&D to drive market              377

TABLE 541         BRAZIL: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          378

TABLE 542         BRAZIL: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)           378

TABLE 543         BRAZIL: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION) 379

TABLE 544         BRAZIL: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 379

TABLE 545         BRAZIL: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)    379

TABLE 546         BRAZIL: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION) 380

TABLE 547         BRAZIL: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)          380

TABLE 548         BRAZIL: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)          381

TABLE 549         BRAZIL: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)          381

9.5.3      MEXICO             381

9.5.3.1   Favorable government policies for R&D and manufacturing to drive market              381

TABLE 550         MEXICO: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          382

TABLE 551         MEXICO: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)           382

TABLE 552         MEXICO: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION) 383

TABLE 553         MEXICO: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 383

TABLE 554        MEXICO: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)    383

TABLE 555         MEXICO: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION) 384

TABLE 556         MEXICO: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)          384

TABLE 557         MEXICO: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)          385

TABLE 558         MEXICO: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION) 385

9.5.4      REST OF LATIN AMERICA          385

TABLE 559         REST OF LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          386

TABLE 560         REST OF LATIN AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)   386

TABLE 561         REST OF LATIN AMERICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)  387

TABLE 562         REST OF LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE,  2022–2029 (USD MILLION)    387

TABLE 563         REST OF LATIN AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)    387

TABLE 564         REST OF LATIN AMERICA: ANALYTICAL TESTING MARKET, BY TYPE,  2022–2029 (USD MILLION)          388

TABLE 565         REST OF LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)           388

TABLE 566         REST OF LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)         389

TABLE 567         REST OF LATIN AMERICA: CRO SERVICES MARKET, BY END USER,  2022–2029 (USD MILLION)          389

9.6         MIDDLE EAST & AFRICA             389

TABLE 568         MIDDLE EAST & AFRICA: CRO SERVICES MARKET, BY REGION,  2022–2029 (USD MILLION)          390

TABLE 569         MIDDLE EAST & AFRICA: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          390

TABLE 570         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,  BY PHASE, 2022–2029 (USD MILLION) 391

TABLE 571         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)  391

TABLE 572         MIDDLE EAST & AFRICA: PRECLINICAL SERVICES MARKET, BY TYPE,  2022–2029 (USD MILLION)          391

TABLE 573         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)    392

TABLE 574         MIDDLE EAST & AFRICA: ANALYTICAL TESTING MARKET, BY TYPE,  2022–2029 (USD MILLION)          392

TABLE 575         MIDDLE EAST & AFRICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)           393

TABLE 576         MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)         393

TABLE 577         MIDDLE EAST & AFRICA: CRO SERVICES MARKET, BY END USER,  2022–2029 (USD MILLION)          394

9.6.1      MIDDLE EAST & AFRICA: RECESSION IMPACT   394

9.6.2      MIDDLE EAST  394

9.6.2.1   Increase in clinical research activities to drive market   394

TABLE 578         MIDDLE EAST: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 395

TABLE 579         MIDDLE EAST: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)       395

TABLE 580         MIDDLE EAST: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,  BY TYPE, 2022–2029 (USD MILLION)            396

TABLE 581         MIDDLE EAST: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          396

TABLE 582         MIDDLE EAST: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)             396

TABLE 583         MIDDLE EAST: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)     397

TABLE 584         MIDDLE EAST: CRO SERVICES MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)          397

TABLE 585         MIDDLE EAST: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)          398

TABLE 586         MIDDLE EAST: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)     398

9.6.3      AFRICA 398

9.6.3.1   Growth in pharmaceutical industry to support market  398

TABLE 587         AFRICA: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          399

TABLE 588         AFRICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)           399

TABLE 589         AFRICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION) 400

TABLE 590         AFRICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 400

TABLE 591         AFRICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)    400

TABLE 592         AFRICA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION) 401

TABLE 593         AFRICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)          401

TABLE 594         AFRICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)          402

TABLE 595         AFRICA: CRO SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)          402

10          COMPETITIVE LANDSCAPE       403

10.1       INTRODUCTION            403

10.2       KEY STRATEGIES/RIGHT TO WIN           403

FIGURE 40         STRATEGIES ADOPTED BY KEY PLAYERS IN CRO SERVICES MARKET            404

10.3       REVENUE SHARE ANALYSIS       405

FIGURE 41         REVENUE ANALYSIS OF KEY PLAYERS, 2021–2023 (USD BILLION)           405

10.4       MARKET SHARE ANALYSIS         405

FIGURE 42         MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023          406

TABLE 596         DEGREE OF COMPETITION: CRO SERVICES MARKET    406

10.5       COMPANY EVALUATION MATRIX          407

10.5.1    STARS  408

10.5.2    EMERGING LEADERS    408

10.5.3    PERVASIVE PLAYERS     408

10.5.4    PARTICIPANTS 408

FIGURE 43         COMPANY EVALUATION MATRIX, 2023 409

10.5.5    COMPANY FOOTPRINT 409

TABLE 597         INDUSTRY FOOTPRINT 409

TABLE 598         SERVICE FOOTPRINT    410

TABLE 599         REGIONAL FOOTPRINT             411

10.6       START-UP/SME EVALUATION MATRIX 411

10.6.1    PROGRESSIVE COMPANIES       411

10.6.2    RESPONSIVE COMPANIES          411

10.6.3    DYNAMIC COMPANIES 412

10.6.4    STARTING BLOCKS       412

FIGURE 44         START-UP/SME EVALUATION MATRIX, 2023      412

10.6.5    COMPETITIVE BENCHMARKING            413

TABLE 600         DETAILED LIST OF KEY START-UPS/SMES         413

TABLE 601         COMPETITIVE BENCHMARKING OF START-UPS/SMES  414

10.7       COMPETITIVE SCENARIOS & TRENDS   414

10.7.1    KEY SERVICES LAUNCHES         414

TABLE 602         KEY SERVICE LAUNCHES, JANUARY 2020–SEPTEMBER 2023              414

10.7.2    KEY DEALS        415

TABLE 603         KEY DEALS, JANUARY 2020– SEPTEMBER 2023    415

10.7.3    OTHER KEY DEVELOPMENTS   416

TABLE 604         KEY EXPANSIONS, JANUARY 2020– SEPTEMBER 2023      416

11          COMPANY PROFILES    417

11.1       KEY PLAYERS   417

(Business overview, Services/Solutions offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and Competitive threats)*

11.1.1    IQVIA INC.         417

TABLE 605         IQVIA INC.: COMPANY OVERVIEW         417

FIGURE 45         IQVIA INC.: COMPANY SNAPSHOT (2022)           418

11.1.2    ICON PLC          422

TABLE 606         ICON PLC: COMPANY OVERVIEW           422

FIGURE 46         ICON PLC: COMPANY SNAPSHOT (2022)             422

11.1.3    THERMO FISHER SCIENTIFIC INC.          427

TABLE 607         THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW              427

FIGURE 47         THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)   428

11.1.4    LABORATORY CORPORATION OF AMERICA HOLDINGS             433

TABLE 608         LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW  433

FIGURE 48         LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022)    434

11.1.5    SYNEOS HEALTH           438

TABLE 609         SYNEOS HEALTH: COMPANY OVERVIEW            438

FIGURE 49         SYNEOS HEALTH: COMPANY SNAPSHOT (2022) 439

11.1.6    WUXI APPTEC  444

TABLE 610         WUXI APPTEC: COMPANY OVERVIEW   444

FIGURE 50         WUXI APPTEC: COMPANY SNAPSHOT (2022)     445

11.1.7    CHARLES RIVER LABORATORIES            449

TABLE 611         CHARLES RIVER LABORATORIES: COMPANY OVERVIEW              449

FIGURE 51         CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2022)              450

11.1.8    PAREXEL INTERNATIONAL CORPORATION       454

TABLE 612         PAREXEL INTERNATIONAL CORPORATION: COMPANY OVERVIEW        454

11.1.9    PHARMARON   458

TABLE 613         PHARMARON: COMPANY OVERVIEW    458

FIGURE 52         PHARMARON: COMPANY SNAPSHOT (2022)      459

11.1.10  FORTREA, INC. 461

TABLE 614         FORTREA, INC.: COMPANY OVERVIEW  461

FIGURE 53         FORTREA, INC.: COMPANY SNAPSHOT (2022)    461

11.1.11  MEDPACE         465

TABLE 615         MEDPACE: COMPANY OVERVIEW          465

FIGURE 54         MEDPACE: COMPANY SNAPSHOT (2022)            465

11.1.12  SGS SA  467

TABLE 616         SGS SA: COMPANY OVERVIEW  467

FIGURE 55         SGS SA: COMPANY SNAPSHOT (2022)    468

11.1.13  FRONTAGE LABS           471

TABLE 617         FRONTAGE LABS: COMPANY OVERVIEW            471

FIGURE 56         FRONTAGE LABS: COMPANY SNAPSHOT (2022) 472

11.1.14  EUROFINS SCIENTIFIC  476

TABLE 618         EUROFINS SCIENTIFIC: COMPANY OVERVIEW  476

FIGURE 57         EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)    476

11.1.15  PSI CRO AG       479

TABLE 619         PSI CRO AG: COMPANY OVERVIEW        479

11.1.16  BIOAGILE          481

TABLE 620         BIOAGILE: COMPANY OVERVIEW          481

11.1.17  FIRMA CLINICAL RESEARCH     483

TABLE 621         FIRMA CLINICAL RESEARCH: COMPANY OVERVIEW      483

11.1.18  ACCULAB LIFE SCIENCES           484

TABLE 622         ACCULAB LIFE SCIENCES: COMPANY OVERVIEW           484

11.1.19  NOVOTECH      485

TABLE 623         NOVOTECH: COMPANY OVERVIEW       485

11.1.20  KCR S.A.             488

TABLE 624         KCR S.A.: COMPANY OVERVIEW 488

11.1.21  LINICAL             490

TABLE 625         LINICAL: COMPANY OVERVIEW             490

11.1.22  ADVANCED CLINICAL  492

TABLE 626         ADVANCED CLINICAL: COMPANY OVERVIEW   492

11.2       OTHER PLAYERS           494

11.2.1    ALLUCENT       494

11.2.2    CLINICAL TRIAL SERVICE          495

11.2.3    GUIRES INC. (PEPGRA HEALTHCARE PVT. LTD.)            496

11.2.4    WORLDWIDE CLINICAL TRIALS 497

11.2.5    CTI CLINICAL TRIAL & CONSULTING    499

*Details on Business overview, Services/Solutions offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.

12          APPENDIX         500

12.1       DISCUSSION GUIDE      500

12.2       KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL             504

12.3       CUSTOMIZATION OPTIONS      506

12.4       RELATED REPORTS       506

12.5       AUTHOR DETAILS         507